<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498407</url>
  </required_header>
  <id_info>
    <org_study_id>CP4055-202</org_study_id>
    <secondary_id>Grantor: CDER</secondary_id>
    <secondary_id>IND/IDE Number: NA</secondary_id>
    <nct_id>NCT00498407</nct_id>
  </id_info>
  <brief_title>A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clavis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clavis Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC)&#xD;
      who have failed a first-line chemotherapeutic regimen containing oxaliplatin and&#xD;
      5-fluorouracil (5-FU) with or without bevacizumab, with or without other Investigational&#xD;
      Medicinal Products (IMPs), will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5&#xD;
      every four weeks until complete response or disease worsening/progressing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre clinical study conducted in the United Kingdom. It is an open label&#xD;
      study designed to investigate objective response rate (RR), the time to progression (TTP) and&#xD;
      the duration of tumor response in patients with colorectal cancer when treated with CP-4055.&#xD;
      The quantitative and qualitative toxicities of the treatment will also be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Objective response rate (RR)</measure>
    <time_frame>October 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Time to progression (TTP)</measure>
    <time_frame>October 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Duration of tumor response</measure>
    <time_frame>October 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Characterize the quantitative and the qualitative toxicities of the CP-4055 treatment in this patient population</measure>
    <time_frame>October 2008</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-4055</intervention_name>
    <description>CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion</description>
    <other_name>ELACYT (TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically or cytologically confirmed metastatic CRC who have failed&#xD;
             a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU)&#xD;
             with or without bevacizumab, with or without other Investigational Medicinal Products&#xD;
             (IMPs)&#xD;
&#xD;
          2. Measurable disease according to Response Criteria In Solid Tumours (RECIST)&#xD;
&#xD;
          3. Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group)&#xD;
             Performance Status&#xD;
&#xD;
          4. Age 18 years or more&#xD;
&#xD;
          5. Life expectancy &gt; 3 months&#xD;
&#xD;
          6. Signed informed consent (IC)&#xD;
&#xD;
          7. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically&#xD;
             sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to&#xD;
             CP-4055 treatment. Nursing patients are excluded.&#xD;
&#xD;
          8. Male and female patients must use acceptable contraceptive methods for the duration of&#xD;
             time on study, and males also for 3 months after the last CP-4055 dose&#xD;
&#xD;
          9. Adequate haematological and biological functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known brain metastases&#xD;
&#xD;
          2. Radiotherapy to more than 30 % of bone marrow&#xD;
&#xD;
          3. Participation in another therapeutic clinical study within 30 days of enrolment or&#xD;
             during this clinical study&#xD;
&#xD;
          4. Concomitant treatment with a non-permitted medication:&#xD;
&#xD;
               -  Alternative drugs&#xD;
&#xD;
               -  High doses of vitamins&#xD;
&#xD;
          5. History of allergic reactions to ara-C or egg&#xD;
&#xD;
          6. Any serious concomitant systemic disorders incompatible with the clinical study (e.g.&#xD;
             uncontrolled inter-current illness including ongoing or active infection)&#xD;
&#xD;
          7. Any significant central nervous system or psychiatric disorder(s) that would hamper&#xD;
             the patient's compliance&#xD;
&#xD;
          8. Pregnancy, breastfeeding or absence of adequate contraception for both male and female&#xD;
             fertile patients&#xD;
&#xD;
          9. Known positive status for HIV and/or hepatitis B or C&#xD;
&#xD;
         10. Drug and/or alcohol abuse&#xD;
&#xD;
         11. Any reason why, in the investigator's opinion, the patient should not participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Cassidy, MBChB, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Beatson West of Scotland Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary, Foresterhill,</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Dept. of Cancer Studies and Molecular Medicine, Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LEI 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macmillan Lead Clinician in Gastro-intestinal Cancer Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <last_update_submitted>June 3, 2009</last_update_submitted>
  <last_update_submitted_qc>June 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jean-Michel Gaullier</name_title>
    <organization>Clavis Pharma</organization>
  </responsible_party>
  <keyword>CP-4055</keyword>
  <keyword>ELACYT(TM)</keyword>
  <keyword>Cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>CRC</keyword>
  <keyword>Second line therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

